Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy

Aguiar-Bujanda, David; Dueñas-Comino, Arancha; Cabello, Camila; Rivero-Vera, José C.; Limeres-González, Miguel Ángel

doi:10.1684/ejd.2017.3149

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantage of Brentuximab therapy is that it is available to patients with both cutaneous and systemic form of anaplastic large-cell CD-30 positive lymphoma [ 4 ] [ 5 ]. Both indications (systemic and cutaneous) for introducing systemic treatment are of significant importance about the clinical management in “problematic patients” [ 4 ] [ 5 ]. The patient we have described did not agree to a biopsy of the paraesophageal-localized lymph node and bilaterally localised inguinal enlarged lymph nodes.…”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!

Popova¹,

Radinov²,

Stavrov³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND:Modern drugs could sometimes be a good solution even to problematic patients. The cutaneous and systemic forms of the CD30 positive anaplastic large T-cell lymphoma could often be described as a suitable target for therapy with Brentuximab vedotin.CASE REPORT:We present the first case of a Bulgarian patient with a histologically confirmed primary cutaneous T-cell CD30+/ALK- large anaplastic cell lymphoma-cALCL (therapeutically resistant to therapy with Methotrexate, radiation therapy and systemic corticosteroid therapy) who was successfully treated with Brentuximab vedotin. In several years, the patient has developed a comparatively fast skin progression as well as an initial systemic one which impacts inguinal and mediastinal nodes. After the implementation of 4 therapy cycles with Brentuximab vedotin, complete regression of the described by previous hospitalisations lymph nodes as well as 80% reduction of the cutaneous and subcutaneous located tumour formations were observed.CONCLUSION:The therapy of CD30+/ALK- anaplastic large T-cell lymphoma is a significant challenge for oncologists and dermatologists because it requires maximally efficient and minimally traumatic treatment in parallel. Therapy with Brentuximab is a new direction which shows extremely good clinical results and can be applied to the cutaneous as well as to the systemic form of anaplastic large-cell CD30 positive lymphoma. The key element by treatment with Brentuximab is suppression of the CD30- expression which, in turn, could be the cause of relapses. On that ground, patients with these lymphomas should be strictly monitored.

show abstract